BNR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Burning Rock Biotech Ltd (BNR) is not a strong buy for a beginner, long-term investor at this time. Despite bullish technical indicators, the company's financial performance is weak, with significant declines in net income and EPS. Additionally, there are no significant positive catalysts, news, or trading trends to support a buy decision. A hold position is recommended until further positive developments occur.
The technical indicators show bullish momentum with a positive MACD histogram (0.943), overbought RSI (86.38), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the stock is near resistance levels (R2: 22.891), suggesting limited upside potential in the short term.
The stock exhibits bullish technical indicators, including positive MACD and strong moving averages. Gross margin increased by 9.96% YoY, indicating some operational efficiency improvements.
No significant news, trading trends, or catalysts have been observed recently. The RSI indicates the stock is overbought, which may lead to a short-term pullback.
In Q4 2025, revenue increased slightly by 0.23% YoY to $126.3M. However, net income dropped significantly to -$15.39M (-81.07% YoY), and EPS fell to -$0.15 (-81.01% YoY). Gross margin improved to 78.03%, up 9.96% YoY, but overall financial performance remains weak.
No recent analyst ratings or price target changes available.
